Neuralytix Expands iD3 System for Spine Surgery
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Fruita, Colorado, August 12, 2026 Neuralytix, LLC announced the full commercial availability of its iD3 System, an FDA 510(k)-cleared...
MONTEREY, Calif., July 29, 2026 Elevation Spine has received U.S. Food and Drug Administration (FDA) 510(k) Clearance for Saber-C®...
BOCA RATON, Fla., June 2026 SurGenTec® has announced U.S. FDA clearance for its ION-L™ Lumbar Facet Fixation System, a...
